Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Dynavax Technologies Corporation (NASDAQ:DVAX) surged 8% Thursday following the announcement of encouraging topline data from ...

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

Dynavax (DVAX) stock gains as the company's Z-1018 shingles shot shows immune response comparable to GSK's (GSK) Shingrix vaccine in a Phase 1/2 trial. Read more here.

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in ...

Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from Dynavax ( (DVAX)) is now available. On August 21, 2025, Dynavax ...

Dynavax beats Q2 expectations with Heplisav-B driving growth. Click here for a full investment analysis of DVAX stock.

Dynavax Technologies Corporation (NASDAQ: DVAX) Q2 2025 Earnings Call Transcript August 7, 2025 Dynavax Technologies ...

Key Points Dynavax Technologies (NASDAQ:DVAX) exceeded analyst expectations in Q2 2025, reporting GAAP revenue of $95.4 million and GAAP diluted EPS of $0.14. HEPLISAV-B, Dynavax's two-dose adult ...

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of +16.67% and +8.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Dynavax Technologies Corp. (DVAX) on Thursday reported earnings of $18.7 million in its second quarter. On a per-share basis, ...